Seminar section introduction III
Kidney cancer: Opportunity for disease specific targeted therapy

https://doi.org/10.1016/j.urolonc.2008.03.014Get rights and content

Reference (1)

  • W.M. Linehan et al.

    Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics

    Clin Cancer Res

    (2007)

Cited by (4)

  • Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review

    2020, Clinical Genitourinary Cancer
    Citation Excerpt :

    For years, systemic therapy along with cytoreductive nephrectomy was the standard of care for metastatic RCC, but the results of the CARMENA trial have called into question the utility of cytoreductive nephrectomy, as sunitinib alone was shown to be not inferior to sunitinib with nephrectomy.3 Treatment of non–clear-cell RCC is challenging given this entity’s rarity, but sunitinib, cabozantinib, or everolimus, a mammalian target of rapamycin (mTOR) inhibitor, are often used in the first-line setting.4-6 Before today’s age of targeted therapies and immunotherapy, interleukin-2 and interferon alfa were the main treatments available for advanced RCC and demonstrated response rates of approximately 10% to 22%, but with significant tolerability issues.7

  • Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT

    2011, Urologic Oncology: Seminars and Original Investigations
    Citation Excerpt :

    Patients with renal cell carcinoma (RCC) continue to present a therapeutic challenge despite improved treatment modalities [1].

  • Targeting the Met signaling pathway in renal cancer

    2009, Expert Review of Anticancer Therapy
View full text